CCA
BIO icon

Column Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Column Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-75
Closed -$44K – 709
2020
Q4 		$44K Sell
75
-35
-32% -$19.9K 0.01% 290
2020
Q3 		$57K Sell
110
-24
-18% -$12.2K 0.02% 229
2020
Q2 		$60K Buy
134
+10
+8% +$4.41K 0.02% 217
2020
Q1 		$43K Sell
124
-58
-32% -$21.3K 0.02% 213
2019
Q4 		$67K Buy
+182
New +$64.2K 0.03% 193

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Column Capital Advisors's BIO Position: Q1 2021 in Review

Column Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2021, closing a stake of 75 shares — an estimated $44K sold.

Column Capital Advisors first reported a position in BIO in Q4 2019 and held it in 5 quarters. The position peaked at $67K in Q4 2019. 491 funds tracked by Wall St. Rank hold BIO as of Q1 2021.

  • Column Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2021 after selling out during the quarter.
  • Column Capital Advisors sold 75 Bio-Rad Laboratories Class A shares in Q1 2021, an estimated $44K.
  • Column Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2019 and held it in 5 quarters.
  • Column Capital Advisors's Bio-Rad Laboratories Class A position peaked at $67K in Q4 2019.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2021.

Based on Column Capital Advisors's 13F filing for Q1 2021, filed 10 May 2021.